A healthcare and life sciences branch of a leading manufacturing company invests primarily in Series A or later companies in digital health, medical devices, genomics and molecular diagnostics technologies, but can expand their focus conditionally. While some of their investments are strategic, the firm is willing to invest outside of corporate strategic areas. The firm is a global investor, and can act as both a strategic partner and a financial investor, depending on the company.
The firm can invest as a strategic manufacturing company, but is also interested in software-enabled technologies and connected devices. While the firm may consider PMA devices, most investments are in 510k-pathway products. For purely digital health products, such as IoT technology, the firm would like to see some revenue and market traction before investing. For both medical devices and digital health, the firm is agnostic to indication. The firm’s interest in genomics and molecular diagnostics primarily relate to the oncology space, and prefer to see technologies with some clinical data.
The firm may take a board seat after investing, if they are the lead or if they have strategic value to offer the portfolio company, but will generally not take a board seat if they are co-investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply